Results
Alembic Pharmaceuticals Q4 PAT Surges 29% YoY
Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹18.48 billion, a 4% YoY growth, with US formulations driving an 11% increase.
Reported PAT surged 29% YoY to ₹2.03 billion, while pre-R&D EBITDA gr
